Overview

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
UCB Pharma SA
Treatments:
Brivaracetam